Health Trials

Smallpox

3

Review clinical trials related to Smallpox. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa

This is a randomized, double-blind, placebo-controlled study which aims to assess the safety, reactogenicity, and immunogenicity after one and two doses of BNT166a or placebo in healthy participants.

Participants needed: 310
Trial details
Phase: Phase 2Age: 18-64Biological sex: AllType: InterventionalSponsor: BioNTech SEUpdated: Mar 4, 2026Locations: 6
Eligibility criteria

Cohort 1: ≥18 to ≤45 years of age [+3]

Have had recent exposure to mpox (defined as close contact with a probable or co... [+5]

Read more
Status: Recruiting

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.

A Two-Phase, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 for Injection Following Single or Multiple Doses in Healthy Subjects

Participants needed: 76
Trial details
Phase: Phase 1Age: 18-50Biological sex: AllType: InterventionalSponsor: China National Biotec Group Company LimitedUpdated: Jan 29, 2026Locations: 1
Eligibility criteria

Subjects voluntarily participate in the study, sign the informed consent form, a... [+3]

Subjects with a known allergy to Tecovirimat drugs, any excipient ingredients in... [+22]

Read more
Status: Available

Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure

The purpose of this clinical protocol is to treat individuals with Tecovirimat after exposure to orthopox viruses.

Trial details
Biological sex: AllType: Expanded AccessSponsor: U.S. Army Medical Research and Development CommandUpdated: Mar 6, 2025
Eligibility criteria

DoD-affiliated personnel (including US civilian employees, contractors and other... [+3]

Has hypersensitivity to tecovirimat [+2]

Read more